Co-Partners
Associate Partners
Co-Partners
Associate Partners
May 17, 2019 04:00 PM IST
April 17, 2019 03:06 PM IST
Net Sales are expected to increase by 15.3 percent Y-o-Y (up 5.2 percent Q-o-Q) to Rs. 307.7 crore, according to Kotak.
April 12, 2019 12:56 PM IST
Net Sales are expected to increase by 30.2 percent Y-o-Y (up 18.8 percent Q-o-Q) to Rs. 347.4 crore, according to Prabhudas Lilladher.
April 11, 2019 08:05 PM IST
The 75 companies can return a median of 49 percent of their total cash and cash equivalents to their shareholders.
April 02, 2019 11:01 AM IST
At 1015 hrs, Dr Lal PathLabs was quoting Rs 1076, up 2.81 percent on the BSE.
February 18, 2019 02:11 PM IST
Prabhudas Lilladher recommended accumulate rating on Dr. Lal PathLabs with a target price of Rs 1070 in its research report dated February 11, 2019.
February 11, 2019 10:48 AM IST
January 17, 2019 08:41 AM IST
Trends on SGX Nifty indicate a positive opening for the broader index in India, a rise of 16 points or 0.15 percent. Nifty futures were trading around 10,941-level on the Singaporean Exchange.
November 14, 2018 05:10 PM IST
Prabhudas Lilladher recommended accumulate rating on Dr. Lal PathLabs with a target price of Rs 1009 in its research report dated November 07, 2018.
November 06, 2018 08:20 PM IST
Operating revenue increased by 14.1 percent to Rs 317.5 crore, the company said in a statement.
November 06, 2018 02:47 PM IST
July 18, 2018 02:19 PM IST
Net Sales are expected to increase by 16 percent Y-o-Y (up 8.4 percent Q-o-Q) to Rs. 289.2 crore, according to Kotak.
July 10, 2018 02:21 PM IST
Bidani will now be serving his notice period in the company.
May 22, 2018 06:18 PM IST
Prabhudas Lilladher recommended accumulate rating on Dr. Lal PathLabs with a target price of Rs 1009 in its research report dated May 14, 2018.
May 19, 2018 01:18 PM IST
The ministry is working with government policy think tank Niti Aayog to prepare a list of diagnostic tests for which prices will be regulated.
April 17, 2018 07:03 PM IST
Net Sales are expected to increase by 18.2 percent Y-o-Y to Rs. 260 crore, according to Edelweiss.
April 06, 2018 03:46 PM IST
The diagnostic firm said it will leverage its Rs 500 crore cash pile to fund its buyout plans in coming months.
November 10, 2017 10:54 AM IST
The company continues to remain highly competitive right across all segments of market ranging from preventive to illness and even to predictive going into the future, said Dilip Bidani, CFO, Dr. Lal PathLabs.
November 10, 2017 08:52 AM IST
The company had posted a net profit of Rs 53 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a BSE filing.
October 13, 2017 05:54 PM IST
Net Sales are expected to increase by 6.4 percent Y-o-Y (up 11.9 percent Q-o-Q) to Rs. 278.9 crore, according to Kotak.
August 08, 2017 11:01 AM IST
In an interview to CNBC-TV18, Doctor Om Manchanda, CEO of Dr Lal Pathlabs spoke about the results and his outlook for the company.
August 08, 2017 09:34 AM IST
The company has registered 11 percent increase in its consolidated net profit to Rs 44.4 crore for the quarter ended June 30 against net profit of Rs 40 crore in the same quarter last year.
August 07, 2017 03:23 PM IST
The company had posted a net profit of Rs 40 crore in the corresponding period of the previous fiscal, Dr Lal PathLabs said in a BSE filing.
July 31, 2017 09:40 AM IST
The liquidity flow continues into Indian markets both from global investors as well as from domestic investors which is pushing valuations of most of the stocks slightly ahead of their long term averages.
July 17, 2017 03:18 PM IST
Ashwani Gujral of ashwanigujral.com suggests buying Century Plyboards, Brigade Enterprises, HUDCO, Aurobindo Pharma and Biocon.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
